Search

Your search keyword '"Cruccu, Giorgio"' showing total 557 results
Start Over Author "Cruccu, Giorgio"
557 results on '"Cruccu, Giorgio"'

1. Trigeminal neuralgia

Author

Ashina, Sait, Robertson, Carrie E., Srikiatkhachorn, Anan, Di Stefano, Giulia, Donnet, Anne, Hodaie, Mojgan, Obermann, Mark, Romero-Reyes, Marcela, Park, Young Seok, Cruccu, Giorgio, and Bendtsen, Lars

Published
2024
Full Text
View/download PDF

10. Joint European Academy of Neurology–European Pain Federation–Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment

Author

Truini, Andrea, primary, Aleksovska, Katina, additional, Anderson, Christopher C., additional, Attal, Nadine, additional, Baron, Ralf, additional, Bennett, David L., additional, Bouhassira, Didier, additional, Cruccu, Giorgio, additional, Eisenberg, Elon, additional, Enax‐Krumova, Elena, additional, Davis, Karen Deborah, additional, Di Stefano, Giulia, additional, Finnerup, Nanna B., additional, Garcia‐Larrea, Luis, additional, Hanafi, Ibrahem, additional, Haroutounian, Simon, additional, Karlsson, Pall, additional, Rakusa, Martin, additional, Rice, Andrew S. C., additional, Sachau, Juliane, additional, Smith, Blair H., additional, Sommer, Claudia, additional, Tölle, Thomas, additional, Valls‐Solé, Josep, additional, and Veluchamy, Abirami, additional

Published
2023
Full Text
View/download PDF

15. Considerations When Using Gabapentinoids to Treat Trigeminal Neuralgia: A Review

Author

De Stefano,Gianfranco, Di Pietro,Giuseppe, Truini,Andrea, Cruccu,Giorgio, Di Stefano,Giulia, De Stefano,Gianfranco, Di Pietro,Giuseppe, Truini,Andrea, Cruccu,Giorgio, and Di Stefano,Giulia

Abstract

Gianfranco De Stefano,* Giuseppe Di Pietro,* Andrea Truini, Giorgio Cruccu, Giulia Di Stefano Department of Human Neuroscience, Sapienza University, Rome, Italy*These authors contributed equally to this workCorrespondence: Giulia Di Stefano, Department of Human Neuroscience, Sapienza University, Rome, Viale Università 30, Rome, 00185, Italy, Tel +39 06 49694209, Email giulia.distefano@uniroma1.itAbstract: Despite the exemplary efficacy of voltage-gated sodium channel blockers as a first-line treatment of trigeminal neuralgia, the pharmacological management of this excruciating facial pain condition remains a major issue, as these first-line drugs produce intolerable side effects in a significant portion of patients. In addition, in patients with concomitant continuous pain, the efficacy of these drugs may drop, thus suggesting the opportunity to test the efficacy of different drug categories. The aim of this review is to provide current, evidence-based, knowledge about the use of gabapentin and other α 2δ ligands in patients with trigeminal neuralgia. We searched for relevant papers within PubMed, EMBASE, the Cochrane Database of Systematic Reviews and the Clinical Trials database (ClinicalTrials.gov), considering publications up to April 2023. Two authors independently selected studies for inclusion and data extraction. The efficacy of α 2δ ligands, gabapentin and pregabalin, has been assessed in seven controlled or open-label studies. Despite the low quality of evidence, the favorable tolerability profile and the possible action on concomitant continuous pain make this drug category of interest for future trials in trigeminal neuralgia.Plain Language Summary: Trigeminal neuralgia is a really excruciating neuropathic pain condition. Although sodium channel blockers are efficacious in most of the patients, the poor tolerability profile and the limited efficacy in patients with concomitant continuous pain represent a major issue over the

Published
2023

16. A cross-sectional study investigating frequency and features of definitely diagnosed diabetic painful polyneuropathy

Author

Truini, Andrea, Spallone, Vincenza, Morganti, Roberto, Tamburin, Stefano, Zanette, Giampietro, Schenone, Angelo, De Michelis, Chiara, Tugnoli, Valeria, Simioni, Valentina, Manganelli, Fiore, Dubbioso, Raffaele, Lauria, Giuseppe, Lombardi, Raffaella, Jann, Stefano, De Toni Franceschini, Luisa, Tesfaye, Solomon, Fiorelli, Marco, Spagnoli, Alessandra, and Cruccu, Giorgio

Published
2018
Full Text
View/download PDF

18. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain

Author

Scholz, Joachim, Finnerup, Nanna B., Attal, Nadine, Aziz, Qasim, Baron, Ralf, Bennett, Michael I., Benoliel, Rafael, Cohen, Milton, Cruccu, Giorgio, Davis, Karen D., Evers, Stefan, First, Michael, Giamberardino, Maria Adele, Hansson, Per, Kaasa, Stein, Korwisi, Beatrice, Kosek, Eva, Lavandʼhomme, Patricia, Nicholas, Michael, Nurmikko, Turo, Perrot, Serge, Raja, Srinivasa N., Rice, Andrew S.C., Rowbotham, Michael C., Schug, Stephan, Simpson, David M., Smith, Blair H., Svensson, Peter, Vlaeyen, Johan W.S., Wang, Shuu-Jiun, Barke, Antonia, Rief, Winfried, and Treede, Rolf-Detlef

Published
2019
Full Text
View/download PDF

21. Trigeminal Neuralgia

Author

Cruccu, Giorgio, Truini, Andrea, Zakrzewska, Joanna M., Martelletti, Paolo, editor, and Steiner, Timothy J., editor

Published
2011
Full Text
View/download PDF

27. A TRPM7 mutation linked to familial trigeminal neuralgia: Omega current and hyperexcitability of trigeminal ganglion neurons

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Gualdani, Roberta, Gailly, Philippe, Yuan, Jun-Hui, Yerna, Xavier, Di Stefano, Giulia, Truini, Andrea, Cruccu, Giorgio, Dib-Hajj, Sulayman D., Waxman, Stephen G., UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Gualdani, Roberta, Gailly, Philippe, Yuan, Jun-Hui, Yerna, Xavier, Di Stefano, Giulia, Truini, Andrea, Cruccu, Giorgio, Dib-Hajj, Sulayman D., and Waxman, Stephen G.

Abstract

Trigeminal neuralgia (TN) is a unique pain disorder characterized by intense paroxysmal facial pain within areas innervated by the trigeminal nerve. Although most cases of TN are sporadic, familial clusters of TN suggest that genetic factors may contribute to this disorder. Whole-exome sequencing in patients with TN reporting positive family history demonstrated a spectrum of variants of ion channels including TRP channels. Here, we used patch-clamp analysis and Ca2+ and Na+ imaging to assess a rare variant in the TRPM7 channel, p.Ala931Thr, within transmembrane domain 3, identified in a man suffering from unilateral TN. We showed that A931T produced an abnormal inward current carried by Na+ and insensitive to the pore blocker Gd3+. Hypothesizing that replacement of the hydrophobic alanine at position 931 with the more polar threonine destabilizes a hydrophobic ring, near the voltage sensor domain, we performed alanine substitutions of F971 and W972 and obtained results suggesting a role of A931-W972 hydrophobic interaction in S3-S4 hydrophobic cleft stability. Finally, we transfected trigeminal ganglion neurons with A931T channels and observed that expression of this TRPM7 variant lowers current threshold and resting membrane potential, and increases evoked firing activity in TG neurons. Our results support the notion that the TRPM7-A931T mutation located in the S3 segment at the interface with the transmembrane region S4, generates an omega current that carries Na+ influx in physiological conditions. A931T produces hyperexcitability and a sustained Na+ influx in trigeminal ganglion neurons that may underlie pain in this kindred with trigeminal neuralgia.

Published
2022

28. Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark:a double-blind, randomised, placebo-controlled, proof-of-concept study

Author

Schott Andersen, Anne Sofie, Maarbjerg, Stine, Noory, Navid, Heinskou, Tone Bruvik, Forman, Julie Lyng, Cruccu, Giorgio, Ashina, Messoud, Bendtsen, Lars, Schott Andersen, Anne Sofie, Maarbjerg, Stine, Noory, Navid, Heinskou, Tone Bruvik, Forman, Julie Lyng, Cruccu, Giorgio, Ashina, Messoud, and Bendtsen, Lars

Abstract

Background: Trigeminal neuralgia is a severe facial pain disorder that is difficult to treat. Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, has proven efficacy in migraine. Erenumab modulates sensory processing in peripheral trigeminal pain pathways in mice and was reported to be effective for patients with trigeminal neuralgia in open-label studies. We aimed to evaluate the efficacy of erenumab in patients with trigeminal neuralgia. Methods: We did a randomised, double-blind, placebo-controlled trial in adults (aged 18–85 years) with idiopathic or classic trigeminal neuralgia as defined by the 3rd edition of the International Classification of Headache Disorders. The trial was based at the Danish Headache Center, Copenhagen University Hospital. Eligible participants had no clinically significant cerebrovascular or cardiovascular disease, had self-reported pain intensity of at least 4 on the 11-point Numeric Rating Scale (0=no pain, 10=worst pain imaginable), and had at least three daily pain paroxysms. After a 1-week pre-screening period, patients entered a 4-week baseline period. Participants who met pain inclusion criteria at the end of the baseline period were randomly assigned (1:1) to receive subcutaneous injections of either erenumab 140 mg or placebo and entered the 4-week follow-up period. Randomisation was done in blocks of 10 using a computer-generated schedule by a third-party company. Participants and assessors were masked to treatment allocation, and erenumab and placebo were packed in identical prefilled syringes. The primary outcome was the number of responders, defined as patients who had a reduction of at least 30% in mean average daily pain intensity during the follow-up period compared with during the baseline period, analysed in the intention-to-treat population. This trial is registered with the European Union Drug Regulating Authorities Clinical Trials Database, EudraCT number 2019–000848–95. F

Published
2022

30. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles

Author

Baron, Ralf, Maier, Christoph, Attal, Nadine, Binder, Andreas, Bouhassira, Didier, Cruccu, Giorgio, Finnerup, Nanna B., Haanpää, Maija, Hansson, Per, Hüllemann, Philipp, Jensen, Troels S., Freynhagen, Rainer, Kennedy, Jeffrey D., Magerl, Walter, Mainka, Tina, Reimer, Maren, Rice, Andrew S.C., Segerdahl, Märta, Serra, Jordi, Sindrup, Sören, Sommer, Claudia, Tölle, Thomas, Vollert, Jan, and Treede, Rolf-Detlef

Published
2017
Full Text
View/download PDF

34. NeuPSIG guidelines on neuropathic pain assessment

Author

Haanpää, Maija, Attal, Nadine, Backonja, Miroslav, Baron, Ralf, Bennett, Michael, Bouhassira, Didier, Cruccu, Giorgio, Hansson, Per, Haythornthwaite, Jennifer A., Iannetti, Gian Domenico, Jensen, Troels S., Kauppila, Timo, Nurmikko, Turo J., Rice, Andew S.C., Rowbotham, Michael, Serra, Jordi, Sommer, Claudia, Smith, Blair H., and Treede, Rolf-Detlef

Published
2011
Full Text
View/download PDF

41. Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review

Author

Di Stefano, Giulia, Di Lionardo, Andrea, Galosi, Eleonora, Truini, Andrea, and Cruccu, Giorgio

Subjects
neuropathic pain, neuroprotective function, treatment, pain, acetyl-L-carnitine, painful peripheral neuropathy, Review, epigenetic mechanism
Abstract

Acetyl-L-carnitine (ALC) has shown a neuroprotective effect in patients with peripheral neuropathies of different etiologies. Preclinical studies demonstrated a central anti-nociceptive action, both in neuropathic and nociceptive pain models. The present review aims to provide the knowledge on the efficacy of ALC in patients with painful peripheral neuropathy, based on the evidence. Consistent with the PRISMA statement, authors searched PubMed, Embase and the Cochrane Database of Systematic Reviews for relevant papers, including those issued before April 2018. Two authors independently selected studies for inclusion and data extraction: only trials including patients with a diagnosis of peripheral neuropathy and involving at least 10 patients were considered for the purposes of this review. Fourteen clinical trials were revised, to provide the level of evidence for neuropathy. To assess the global efficacy of ALC in painful peripheral neuropathy, a meta-analysis of four randomized controlled trials was performed. Mean difference in pain reduction as measured on a 10-cm VAS, and 95% CIs were used for pooling continuous data from each trial. Four randomized controlled trials tested ALC in patients with neuropathy secondary to diabetes and to antiretroviral therapy for HIV. Compared to placebo, ALC produced a significant pain reduction equal to 20.2% (95% CI: 8.3%-32.1%, P

Published
2019

44. Dissecting pain processing in adolescents with Non‐Suicidal Self Injury: Could suicide risk lurk among the electrodes?

Author

Leone, Caterina, primary, Galosi, Serena, additional, Mollica, Cristina, additional, Fortunato, Mattia, additional, Possidente, Chiara, additional, Milone, Valeria, additional, Misuraca, Sofia, additional, Berillo, Luana, additional, Truini, Andrea, additional, Cruccu, Giorgio, additional, Ferrara, Mauro, additional, and Terrinoni, Arianna, additional

Published
2021
Full Text
View/download PDF

45. Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis

Author

Di Stefano, Giulia, Di Lionardo, Andrea, Di Pietro, Giuseppe, Cruccu, Giorgio, and Truini, Andrea

Subjects
Article Subject
Abstract

Despite an increasing number of available therapies, the treatment of neuropathic pain remains a major issue. Systematic reviews and meta-analyses indicate that only a minority of patients with neuropathic pain have an adequate response to pharmacological treatment and that most drugs have dose-limiting side effects. We conducted a systematic review and meta-analysis of randomised controlled trials published in the last five years. We searched for relevant papers within PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and the Clinical Trials database (ClinicalTrials.gov). Two authors independently selected studies for inclusion, data extraction, and bias assessment. We identified 39 randomised controlled trials and included 16 in the meta-analysis. Trial outcomes were generally modest even for first-line drugs such as tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, and gabapentinoids. Many drugs acting on new pain targets are currently under development. Clinical data are currently available for sodium channel isoform-specific antagonists, anti-nerve growth factor molecules, and fatty acid amide hydrolase inhibitors.

Published
2021
Full Text
View/download PDF

46. Trigeminal Neuralgia TRPM8 Mutation Enhanced Activation, Basal [Ca2+]i and Menthol Response

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Gualdani, Roberta, Yuan, Jun-Hui, Effraim, Philip R., Di Stefano, Giulia, Truini, Andrea, Cruccu, Giorgio, Dib-Hajj, Sulayman D., Gailly, Philippe, Waxman, Stephen G., UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Gualdani, Roberta, Yuan, Jun-Hui, Effraim, Philip R., Di Stefano, Giulia, Truini, Andrea, Cruccu, Giorgio, Dib-Hajj, Sulayman D., Gailly, Philippe, and Waxman, Stephen G.

Abstract

Objective To assess the functional effects of a variant, c.89 G > A (p.Arg30Gln), in the transient receptor potential melastatin 8 (TRPM8) cold-sensing, nonselective cation channel, which we have previously identified in a patient with familial trigeminal neuralgia. Methods We carried out Ca2+ imaging and whole-cell patch-clamp recording. Results The TRPM8 mutation enhances channel activation, increases basal current amplitude and intracellular [Ca2+] in cells carrying the mutant channel, and enhances the response to menthol. Conclusions We propose that Arg30Gln confers gain-of-function attributes on TRPM8, which contribute to pathogenesis of trigeminal neuralgia in patients carrying this mutation.

Published
2021

49. Refractory Chronic Pain Screening Tool (RCPST): A Feasibility Study to Assess Practicality and Validity of Identifying Potential Neurostimulation Candidates

Author

Baron, Ralf, Backonja, Misha M., Eldridge, Paul, Levy, Robert, Vissers, Kris, Attal, Nadine, Buchser, Eric, Cruccu, Giorgio, De Andrés, Jose, Hansson, Per, Jacobs, Marilyn, Loeser, John D., Prager, Joshua P., Stanton Hicks, Michael, Regnault, Antoine, Van den Abeele, Carine, and Taylor, Rod S.

Published
2014
Full Text
View/download PDF

50. Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases

Author

Padua, Luca, Briani, Chiara, Jann, Stefano, Nobile-Orazio, Eduardo, Pazzaglia, Costanza, Morini, Alberto, Mondelli, Mauro, Ciaramitaro, Palma, Cavaletti, Guido, Cocito, Dario, Fazio, Raffaella, Santoro, Lucio, Galeotti, Francesca, Carpo, Marinella, Plasmati, Rosaria, Benedetti, Luana, Schenone, Angelo, Marchettini, Paolo, and Cruccu, Giorgio

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results